Results 331 to 340 of about 93,898 (384)

The impact of steroid-sparing biologic therapies on weight loss in obese individuals with severe eosinophilic asthma

European Respiratory Journal, 2023
Extract Asthma and obesity are prevalent disorders with significant impact on public health. Obesity is a reported risk factor for the development of asthma and is associated with increased exacerbation rates, medication usage and higher symptoms scores ...
A. Nanzer, Victoria Taylor, A. Hearn, J. Kavanagh, Tanya Patrick, L. Green, L. Thomson, J. Lam, Mariana Fernandez, C. Roxas, G. D'ancona, B. Kent, J. Dhariwal, D. Jackson   +13 more
semanticscholar   +1 more source

“Refractory” Eosinophilic Airway Inflammation in Severe Asthma

American Journal of Respiratory and Critical Care Medicine, 2004
It has been suggested that patients with refractory eosinophilic airway inflammation represent a separate “eosinophilic” asthma phenotype associated with increased morbidity and a poor prognosis. To investigate whether persistent eosinophilia in these patients is a fixed feature or can still be modified by treatment, we investigated the effect of high ...
ten Brinke, A., Zwinderman, A. H., Sterk, P. J., Rabe, K. F., Bel, E. H.   +4 more
openaire   +2 more sources

Mepolizumab for eosinophilic severe asthma: recent studies

Expert Opinion on Biological Therapy, 2015
In September 2014 two large clinical studies of the anti-IL-5 monoclonal antibody mepolizumab in severe asthma were published in the New England Journal of Medicine (MENSA and SIRIUS).Eosinophilic inflammation has long been recognised as a feature of asthma.
Douglas S, Robinson, Harsha H, Kariyawasam   +1 more
openaire   +2 more sources

Histamine, Basophils and Eosinophils in Severe Asthma

Clinical Science, 1979
1. Arterial and venous whole blood and plasma histamine concentrations and eosinophil and basophil counts were determined in five patients with acute severe asthma who had not previously received steroid therapy, in five who had been maintained on steroid therapy and in a control group of nine patients with acute non-respiratory illnesses.
T J, Charles, S J, Williams, A, Seaton, C, Bruce, W H, Taylor   +4 more
openaire   +2 more sources

Prognostic factors in severe eosinophilic asthma

Monitoring Airway Disease, 2018
Introduction: Uncontrolled Severe Eosinophilic Asthma (USEA) represents a challenging health problem. Characterize variables that predict poor control in this patients to will improve its management. The aim was identify the factors of poor control of severe eosinophilic asthma. Methodes: Were collected 78 patients of our Asthma Severe Unit.
Filipe Gonçalves Dos Santos Carvalho, Clara Padró Casas, María Basagaña Torrento, Marisa Rivera Ortun, María Del Mar Martínez Colls, Carlos Pollan Guisasola, Alicia Francoso Vicente, Eva Martínez Cáceres, Aina Teniente, Albert Roger, Juan Ruiz Manzano, Carlos Martinez Rivera   +11 more
  +6 more sources

Mepolizumab for severe eosinophilic asthma

Expert Review of Respiratory Medicine, 2013
In this large (616 patients), double-blind, placebo-controlled, dose-ranging study of mepolizumab (a monoclonal antibody that blocks IL-5 binding to its receptor), patients were given placebo, 75-, 250- or 750-mg mepolizumab by intravenous infusion every 4 weeks for 1 year.
openaire   +2 more sources

RELIght: A two‐year REal‐LIfe study of mepolizumab in patients with severe eosinophilic asTHma in Greece: Evaluating the multiple components of response

Allergy. European Journal of Allergy and Clinical Immunology, 2022
R E FE R E N C E S 1. Zuberbier T, Aberer W, Asero R, et al. Endorsed by the following societies: AAAAI, AAD, AAIITO, ACAAI, AEDV, APAAACI, ASBAI, ASCIA, BAD, BSACI, CDA, CMICA, CSACI, DDG, DDS, DGAKI, DSA, DST, EAACI, EIAS, EDF, EMBRN, ESCD, GA2LEN ...
M. Kallieri, E. Zervas, E. Fouka, Konstantinos Porpodis, Marija Hadji Mitrova, E. Tzortzaki, M. Makris, Maria Ntakoula, A. Papaioannou, P. Lyberopoulos, K. Dimakou, S. Koukidou, S. Ampelioti, A. Papaporfyriou, K. Katsoulis, M. Kipourou, N. Rovina, K. Antoniou, S. Vittorakis, P. Bakakos, P. Steiropoulos, K. Markopoulou, Panteleimon Avarlis, Ιlias C. Papanikolaou, Miltiadis Markatos, Eleni Gaki, K. Samitas, K. Glynos, S. Papiris, D. Papakosta, N. Tzanakis, M. Gaga, K. Kostikas, S. Loukides   +33 more
semanticscholar   +1 more source

Overcoming Barriers to Remission in Severe Eosinophilic Asthma: Two‐Year Real‐World Data With Benralizumab

Clinical and Experimental Allergy
Benralizumab has been reported to lead to clinical remission of severe eosinophilic asthma (SEA) at 1 year in some patients. However, whether this is maintained over a longer term remains unclear.
D. J. Jackson, Hassan Burhan, H. Rupani, Paul E. Pfeffer, I. Clifton, Shoaib Faruqi, J. Dhariwal, P. Patel, T. Morris, Joe Lipworth, Michael Watt, C. Lupton, S. Dube, J. Hickey, A. Nanzer   +14 more
semanticscholar   +1 more source

Mepolizumab in children and adolescents with severe eosinophilic asthma not eligible for omalizumab: a single Center experience

Journal of Asthma
Background Mepolizumab is an anti-interleukin-5 monoclonal antibody shown to reduce asthma exacerbations in adults and adolescents with severe eosinophilic asthma.
MBChB Y. T. Lim, MD T. C. Williams, R. J. L. PhD, M. M. E. PhD   +3 more
semanticscholar   +1 more source

Mixed Severe Eosinophilic and Allergic Asthma

The Singapore Family Physician, 2022
Difficult-to-treat asthma is asthma that is uncontrolled despite high intensity treatment. Patients with severe asthma are a subset of this group who remain uncontrolled despite addressing contributory factors, necessitating the use of add-on therapies including biologics. Currently available asthma biologics largely target type 2 inflammatory pathways
openaire   +1 more source